0.71
-0.0034(-0.48%)
Currency In USD
| Previous Close | 0.71 |
| Open | 0.75 |
| Day High | 0.75 |
| Day Low | 0.67 |
| 52-Week High | 3.65 |
| 52-Week Low | 0.25 |
| Volume | 5.05M |
| Average Volume | 5.26M |
| Market Cap | 21.48M |
| PE | -0.14 |
| EPS | -4.99 |
| Moving Average 50 Days | 0.64 |
| Moving Average 200 Days | 1.41 |
| Change | -0 |
If you invested $1000 in Moleculin Biotech, Inc. (MBRX) since IPO date, it would be worth $0.99 as of July 31, 2025 at a share price of $0.711. Whereas If you bought $1000 worth of Moleculin Biotech, Inc. (MBRX) shares 5 years ago, it would be worth $6.87 as of July 31, 2025 at a share price of $0.711.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin
GlobeNewswire Inc.
Yesterday at 12:35 PM GMT
– New patent enhances market position in Europe HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeti
Moleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
GlobeNewswire Inc.
Jul 22, 2025 12:45 PM GMT
– Video webcast now available on-demand HOUSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard
Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships
GlobeNewswire Inc.
Jul 17, 2025 12:25 PM GMT
Moleculin Biotech, Inc. Adriano Treve 40+ year career at Roche founded on dedication to bringing new innovative medicines to patients and making them accessible HOUSTON, July 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX)